Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bringing HIV care to the community: a new test in zambia

NCT ID NCT02776254

Disease control Sponsor: Centre for Infectious Disease Research in Zambia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study in Zambia is testing whether community-based and streamlined models of antiretroviral therapy (ART) care can help people living with HIV stay in treatment. It involves about 3,100 HIV-positive adolescents and adults who are not acutely ill. Participants may receive care through point-of-care testing for rapid ART initiation, community or urban adherence groups, or prescription refills. The goal is to see if these approaches improve retention in care and are acceptable, feasible, and cost-effective compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Differentiated care models for antiretroviral therapy (ART) delivery, including point-of-care testing, community adherence groups, and prescription refills
What this could lead to
If successful, this could show that community-based ART delivery is a practical way to keep more people with HIV in care, potentially improving long-term health and reducing transmission.
What could go wrong
The study is observational in nature and focuses on feasibility and implementation, so it may not prove which model works best. Results may also depend on local context and may not generalize to other settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

3,100 people

The number who actually took part.

Started

Mar 2016

Finished

Jul 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * HIV-positive adolescents and adults (\> 14 years of age) * Last CD4 count (obtained within the last six months) \> 200 * Not acutely ill * For CAGs, UAGs, and Fast-Track models: on ART for at least 6 months * For the START model: ART naïve and meet the Zambian HIV guidelines for treatment initiation Exclusion Criteria: * For CAGs, UAGs: Inability to participate in the group activities due to cognition deficits or mental illness. * Unable to provide consent or unwilling to participate in study * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

  • Centre for Infectious Disease Research in Zambia

    Lusaka, Lusaka Province, 10101, Zambia

More trials for these conditions

Other studies related to the condition(s) this trial covers.